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Background: Home telemonitoring has developed considerably over recent years in chronic diseases in order to
improve communication between healthcare professionals and patients and to promote early detection of deteriorating
health status. In the nephrology setting, home telemonitoring has been evaluated in home dialysis patients but data are
scarce concerning chronic kidney disease (CKD) patients before and after renal replacement therapy. The eNephro study
is designed to assess the cost effectiveness, clinical/biological impact, and patient perception of a home telemonitoring
for CKD patients. Our purpose is to present the rationale, design and organisational aspects of this study.
Methods: eNephro is a pragmatic randomised controlled trial, comparing home telemonitoring versus usual care in
three populations of CKD patients: stage 3B/4 (n = 320); stage 5D CKD on dialysis (n = 260); stage 5 T CKD treated with
transplantation (n= 260). Five hospitals and three not-for-profit providers managing self-care dialysis situated in three
administrative regions in France are participating. The trial began in December 2015, with a scheduled 12-month
inclusion period and 12 months follow-up. Outcomes include clinical and biological data (e.g. blood pressure,
haemoglobin) collected from patient records, perceived health status (e.g. health related quality of life) collected from
self-administered questionnaires, and health expenditure data retrieved from the French health insurance database
(SNIIRAM) using a probabilistic matching procedure.
Discussion: The hypothesis is that home telemonitoring enables better control of clinical and biological parameters as
well as improved perceived health status. This better control should limit emergency consultations and hospitalisations
leading to decreased healthcare expenditure, compensating for the financial investment due to the telemedicine
system.
Trial registration: This study has been registered at ClinicalTrials.gov under NCT02082093 (date of registration:
February 14, 2014).
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Chronic illness is the leading cause of disability and
death worldwide [1], accounting for the majority of
healthcare expenditures. Care for the chronically ill re-
quires a multiplicity of providers, often resulting in frag-
mentation at multiple locations. Care coordination
becomes an important issue since significant proportions
of the population are affected. In the nephrology setting,
Patients with chronic kidney disease (CKD) may remain
asymptomatic at the early stages of the disease, leading to
suboptimal care [2–4]. It is well documented that coordin-
ation of care between healthcare providers and multidiscip-
linary care teams is associated with earlier nephrology
referral and reduced morbidity, mortality, overall cost and
number of consultations [5]. Many countries have searched
for ways to improve care coordination. Multidisciplinary
care clinics have incited much interest while another possi-
bility, telemedicine, has received relatively little attention
[6]. French legislators have nevertheless recognised the po-
tential of five telemedicine applications: teleconsultation,
tele-expertise, telemonitoring, tele-assistance and coordin-
ation of medical response [7].
One promising application is home telemonitoring, a
solution where active patient participation is a central
component. Communication is facilitated between the
patient and healthcare professionals as is interaction be-
tween healthcare providers. The characteristic feature of
this mode of intervention is its capacity to strengthen
patient follow-up, allowing rapid detection of early
symptoms signalling potential deterioration of the pa-
tient’s health status. Theoretically, better control of
chronic illness would have a significant impact on over-
all healthcare, limiting expenditures and reducing the
need for acute care and hospitalisation. Several studies
have demonstrated that telemonitoring enables better
control of blood pressure, blood glucose, and asthma
symptoms [8]. Telemonitoring would also improve
patient autonomy by helping patients to a better under-
standing and control of their chronic disease and
disease-related symptoms, an important incentive for
treatment adherence.
Telemedicine has been evaluated in the nephrology
setting for the follow-up of home dialysis patients. A
clinical benefit has been demonstrated for patients on
peritoneal dialysis and haemodialysis in satellite out-
patient dialysis units, with a reduction in the number of
hospitalisations [9–11]. For renal transplantation, data
are scarce in the literature [12] and no telemedicine data
are available for CKD stage 3-4 patients.
Very few studies have explored the cost-effectiveness
of telemedicine for the management of chronic disease
[13]. One study conducted in the United States among
patients with chronic obstructive pulmonary disease and
heart failure demonstrated a 4.3% reduction in mortalityand a 9.8% reduction in cost [14]. To date no study has
addressed the question for CKD patients.
The French national investments in the future
programme initiated in 2010 included a tender designed
to stimulate the development of economic models in the
eHealth field (esante.gouv.fr/actus/politique-publique/).
Specifically, healthcare providers were encouraged to per-
form studies in cooperation with industrial partners to
demonstrate the usefulness of large-scale programmes of-
fering complete service packages. Designed in this frame-
work, eNephro was selected with its industrial promoter,
Pharmagest Interactive (http://www.pharmagest.com). This
background has provided a unique opportunity to evaluate
the cost-effectiveness of a novel technique for home tele-
monitoring incorporating an expert system and centred on




The main objective of the eNephro study is to determine the
cost-effectiveness of a telemedicine system compared with
usual care, targeting blood pressure and proteinuria levels in
stage 3B/4 CKD patients and 1-year duration of acute-care
hospitalisation in dialysis and transplantation patients.
Secondary objectives focus on the cost-effectiveness of
telemedicine to improve specific outcomes: clinical and
biological parameters, perceived health status.
Study organisation
The eNephro study is coordinated by the Nancy University
Hospital. Patients are recruited in eight centres located in
three administrative regions in France: 3 University
Hospitals (Nancy, Lille,Bordeaux), 2 General Hospitals
(Dunkerque, Boulogne sur Mer), and 3 not-for-profit
healthcare providers managing self-care dialysis (peritoneal
dialysis and home haemodialysis; outpatient satellite dialy-
sis units) namely, ALTIR Lorraine, AURAD Aquitaine, and
SANTELYS DIALYSE Nord Pas-de-Calais. A steering
committee composed of members delegated by the eight
above-mentioned centres and the industrial promoter
meets quarterly to assess study progress and make deci-
sions regarding study logistics. A scientific committee,
composed of nephrologists, epidemiologists, and a health
economist, works on study design, protocol and promo-
tion. An industrial committee including a project director,
an information technology director, and a clinical trial
manager is in charge of project conception and coordin-
ation, information technology development and the de-
ployment of the eNephro plateform.
Study design and population
The eNephro study is a pragmatic randomised con-
trolled trial (RCT) which aims to compare nephrology
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usual care in CKD patients at different stages of the dis-
ease. Three populations are recruited with the following
inclusion criteria: age ≥ 18 years; ability to use a tablet de-
vice (alone or with assistance); population 1: stabilised
stage 3B or stage 4 CKD with nephrology management of
less than 3 years; population 2: stage 5D CKD treated by
homecare peritoneal dialysis (PD) or out centre haemodi-
alysis (HD); population 3: stage 5 T CKD treated by renal
transplantation for 3–12 months. Non-inclusion criteria
are: dialysis after renal transplantation failure; organ trans-
plantation other than kidney; life expectancy < 1 year.
Patient census and enrolment
During the 24-month inclusion period, participating
centres are invited to enrol eligible patients attending a
pre-inclusion medical visit (V0) where inclusion and
non-inclusion criteria are validated (Fig. 1). An inclusion
visit (V1) is conducted one month later as a standard
nephrology consultation with a physical examination,
blood and urine tests according to guidelines of the
French health authorities (HAS) [15–17], and thera-
peutic adjustment as needed.Pre-inclusion visit (V0)
Inclusion and non-inclusion criteria are validated
Patient receives oral and written information
from the nephrologist
Inclusion visit (V1 = V0 + 1 month)
Standard nephrology consultation




Intermediary visit (V2 = V1 + 6 months)
Standard nephrology consultation
compliance questionnaire
End of follow-up visit (V3 = V1 + 12 months)
Standard nephrology consultation 
Completion of study questionnaires:
Quality-of-life, anxiety/depression, compliance
System acceptability (telemedicine group)
Fig. 1 Flow-chart of the eNephro studyAt the end of the inclusion visit, eligible patients are
informed about the eNephro study and asked to sign an
informed consent form. Patients who agree to participate
in the study are randomly assigned to a study group
(intervention or control) using a random number gener-
ator integrated in the telemedicine system. Randomisation
is performed by balanced blocks of 20 and stratified
by -participating centre and population (1, 2, or 3). Partici-
pating patients are then referred to a clinical research
nurse who collects pertinent data (see data collection
below) and assists patients in filling out the study ques-
tionnaires (see outcomes of interest below). Patients
assigned to the intervention group are given a commer-
cially available 10-inch tablet device with instructions for
use of the telemedicine patient interface.
Patient follow-up
The follow-up period is set at 12 months. Patients are
scheduled for an intermediary visit at six months (V2) and
a final end-of-study visit at 12 months (V3), conducted
with the same protocol as the inclusion visit (V1). Patients
in the intervention group are asked to respond to a ques-
tionnaire on the acceptability of the telemedicine system
in addition to the other questionnaires (Fig. 1).
The nephrology care schedule for patients in popula-
tions 1 and 2 abides by the French recommendations
[10, 15, 17], likewise for transplanted patients (population
3) in the control group. For transplanted patients in the tel-
emonitoring group, considering the number of visits regu-
larly scheduled during the first post-transplantation year
[17], the Medical team has the possibility of cancelling
every other in centre visit when clinical and biological re-
sults, transmitted by the patient are in the target and no
symptom declared. Each patient’s telemedicine system
transmits the following information to the data platform:
body weight; body temperature; pulse rate; patient-
measured systolic and diastolic blood pressure for the last
three days; patient-assessed presence of symptoms includ-
ing vertigo, short breath, fatigue, oedema, abdominal pain,
deterioration of general health status. The telemedicine sys-
tem also transmits to the data platform information issuing
from medical laboratories, e.g. the biological parameters
recommended by the French authorities (HAS) for the
follow-up of kidney transplant recipients on samples taken
three days before scheduled visits.
Description of the eNephro telemedicine system
eNephro is an eHealth information technology specifically
developed for the care of CKD patients at all stages of the
disease. This web-based application, harboured by secure
servers according to French regulations, ensures the secur-
ity, confidentiality, integrity, sustainability, availability, re-
versibility and tracability of collected data. As a web-based
application, eNephro is accessible from any web browser.
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tronic medical record, a secure messaging application
used for communication between healthcare profes-
sionals and patients, an agenda for scheduling medical
visits, and a telesurveillance application specifically de-
signed for each population studied. In addition, eNephro
harbours several expert systems, e.g. clinical decision
support tools, for analysing patient data (Fig. 2).
eNephro’s expert systems issued from collaboration
between the Lorraine Research Laboratory in Computer
Science and its Applications (LORIA1) and nephrolo-
gists. These expert systems have been used since 2000
by end-stage renal disease (ESRD) patients on home dia-
lysis [18–21], and 2006 by kidney transplant recipients
[12]. An expert system for stage 3B/4 CKD patients was
specifically developed for the purpose of this study.
eNephro’s telemonitoring system enables remote col-
lection of clinical parameters measured by the patient
and biological parameters determined by medical labora-
tories. The expert systems perform an automatic analysis
of collected data on a daily basis. This automatic analysis
filters the large data mass corresponding to normal
situations not requiring any particular action and re-
cords charts to be examined at the next scheduled
visit. A clinical decision support algorithm modelling
medical reasoning is included in the system to detect
situations of risk.
These expert systems are based on a Bayesian approach
[22, 23]. An alert is generated when the analysis of theFig. 2 The eNephro systemclinical and biological data indicates with high probability
an alteration of the patient’s health status, before the devel-
opment of clinical manifestations. The alerts generated by
the expert systems are designed for early detection of the
following situations: risk of dehydration/hyperhydration,
poor blood pressure control, elevated proteinuria, poor an-
aemia control, occurrence of a complication, recognised
with predefined symptoms.
Users (patients and healthcare professionals) connect via
their user-dedicated interface secured with a strong au-
thentication device: Public Key Infrastructure. Healthcare
professionals use their own computer to access eNephro
and patients are equipped with a tablet device.
Patient interface
Patients can access information concerning their per-
sonal situation. Patient interface functions are described
in Table 1.
Health practitioner interface
Daily surveillance is ensured by a coordinating nurse
who processes incoming data and alerts, handles aspects
within his/her competency and transfers other informa-
tion to the centre’s referral nephrologist. The referral
nephrologist builds up patients’ medical records, man-
ages the enrolment process, and performs intermediary
and final follow-up visits. The referral nephrologist is
also responsible for recording events occurring during
the follow-up period, managing daily alerts transmitted
Table 1 eNephro patient interface
Function Patient input Patients have access to:
Messages Messages for care team Messages from the care team
Agenda Visit schedule
Recalls Recalls concerning data collection
and/or planned visits
Contacts Medical team, clinical research nurses
Documents Information concerning care received outside
the nephrology setting
Medical documents shared by the
care team
Medicinal treatment Latest prescription written by the
nephrologist
Patient data
Dialysis patient: Data on HD or PD sessions Prescription for dialysis History
of HD or PD sessions
CKD patient: Clinical home monitoring (blood
pressure, weight dyspnoea, oedema, fatigue)
Data collection: every 2 weeks
Time course graphs of clinical parameter
values History of data collection (function:
clinical symptoms)
Renal transplant patient: Clinical home monitoring
(blood pressure, weight dyspnoea, oedema, fatigue)
Data collection: from every week to every month
depending on time since transplantation
Events All patients: Any change in health status or
medicinal treatment
Clinical symptoms Time course graphs of clinical parameter values
Laboratory results Laboratory test results reported by the Clinical
Research Nurse
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messages. The patient’s general practitioner can consult
the patient’s medical record at any time. Medical labora-
tories transfer biological results directly to the data pro-
cessing platform.
Data collection
* Data recorded at inclusion and during follow-up
An electronic case report form (eCRF) is used to collect
socio-demographic, clinical, biological and therapeutic
data from patient records at specified time intervals in
the three patient populations (Table 2).
Study completion is noted as are patient dropouts to-
gether with the reason (lost to follow-up, medical decision,
consent withdrawal, change in disease stage, death). All
data are collected and checked for completeness by nine
trained clinical research nurses. An independent clinical
research nurse compares 10% of the completed eCRFs for
consistency with the patient’s medical record.
* Economics data
Cost values correspond to the tariffs set by the
French healthcare fund. Only direct costs are taken
into account for the cost analysis. Two types of cost
are considered: 1) intervention-related cost (computer
equipment, maintenance, personnel training for the tele-
medicine system), recovered from the telemedicine systemsupplier; 2) patient management-related costs (hospitalisa-
tion, consultation, home visits by nurses, complementary
explorations, drugs and medical devices, health transport).
This part of the economics data stems from the French
health insurance database SNIIRAM2 that contains indivi-
dualised, anonymous and linkable data. Prospectively re-
corded for all beneficiaries of healthcare in France,
SNIIRAM covers the entire French population (66 million
inhabitants). Data recorded include all medical expend-
iture reimbursements for long-term disabling diseases, e.g.
CKD. A probabilistic data linkage method [24] will be ap-
plied to identify patients included in the eNephro study
within the anonymous SNIIRAM database.
For each population, mean cost per patient and mean
cost per group (intervention vs control) are estimated,
allowing to calculate an Incremental Cost Effectiveness
Ratio (ICER) of telemedicine as compared with usual
care. The ICER relates the overall costs to the primary
endpoint for each population.
Outcomes of interest
Outcomes of interest are presented in Table 3.
Statistical analyses and sample size
Data processing and statistical analysis are performed by
the clinical epidemiology centre of Nancy using SAS®
software version 9.5 (SAS Institute, Inc., Cary, N.C.).
Table 2 Data recorded at inclusion and during follow-up
Category Data collected Inclusion 6 months 12 months
Sociodemographic data Age, sex, residence (French administrative district), social-occupational
category [32] Educational level, housing, marital status
X
Clinical data CKD history X
Medical history and risk factors X
General health status, weight, estimated dry weight (population 2), blood
pressure, other clinical measurements
X X X
Participation in a patient education programme within the last six months X X X
Status of the vascular access or the peritoneal catheter (population 2) X X X
Intercurrent eventsa occurring within the last six months X X
Biological data Laboratory test results as recommended by the French health authorities
(HAS) [15, 17]
X X X
Therapeutic data Dialysis history (populations 2 and 3) X
Transplantation history (population 3) X
Dialysis prescriptions (population 2) X X X
Medications (drug names, dosages) X X X
aIntercurrent events: major cardiovascular and/or nephrological events, hospitalisations, death, rejection of the telemedicine system
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The statistical analysis plan includes the following proce-
dures for each of the three study populations:
(i) A description of the patients included in each
group (intervention, control): number of patients,
socio-demographic, clinical, biological and therapeutic
parameters. To check the comparability of patientTable 3 Outcomes of interest in the e-nephro study
Populations Outcomes o
Primary outcome of interest
Population 1 Cost-result r
and diastolic
≤ 50 mg/mm
Populations 2 and 3 Cost-result r
hospitalisatio
Secondary outcomes of interest




1, 2 and the
Intervention group of populations 1, 2,






Populations 1 and 3 1-year chang
Population 3 Number of p
number of u
Population 2 Event-free su
dialysis or ho
Anaemia con
of transferringroups, the main features are compared using the χ2
test for qualitative variables, analysis of variance or
the Mann-Whitney test for quantitative variables.
(ii)A description of deviations from the protocol.
(iii)Inter-group comparison of clinical outcomes and
cost-result ratios, with adjustment for any
characteristic differing between two groups.
Intention-to-treat analysis is applied. The percentagef interest
atio, where result is achievement of blood pressure (systolic≤ 130
≤ 80 mmHg) and proteinuria (≤0.5 g/24 h or proteinuria/creatininuria
ol) recommended targets at V3 [33].
atio, where result is the cumulative number of days of acute-care
n over the 1-year study period (from V1 to V3).
ompliance measured by the French questionnaire by Girerd [34]
ression level, measured with the Hospitalization Anxiety Depression
) [35, 36]
e, measured with the KDQoL V36 questionnaire [37] for populations
ReTransQoL questionnaire [38] for population 3
of the telemedicine system, measured with the French version of
ser Technology Acceptability Questionnaire (WSD SUTAQ) for
ng projects [39, 40].
dropout rate from the telemedicine system will also be considered
of the patient acceptability.
e in glomerular filtration rate measured with the MDRD formula [41]
lanned nephrology outpatient visits actually performed, and the
nplanned visits and hospitalisations over the 1-year study period
rvival at 1 year, an event being defined here as return to in-centre
spitalisation
trol, defined as achievement of haemoglobin, ferritin and coefficient
saturation recommended targets
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pressure and proteinuria targets is compared
between the intervention and control groups using
a logistic regression model. For populations 2 and 3,
mean durations of acute-care hospitalisation and cost-
result ratios are compared between the intervention
and control groups using linear regression models.
* Sample size
Sample size calculations were made to demonstrate su-
periority based on the estimated proportions/mean dif-
ference of the primary outcome of interest between
groups (telemedicine versus usual care). The alpha risk
was set at 5% and the beta risk at 10%. The total number
of patients to include is 320 for population 1 (difference
of 15% in the primary outcome of interest between
groups), and 260 for populations 2 and 3 (mean differ-
ence: 6 days, standard deviation: 15 days for population
2 and mean difference: 8 days, standard deviation:
20 days for population 3).
Discussion
There have been very few assessments of the medicoeco-
nomic interest of home telemonitoring for chronic dis-
eases, and the quality of evidence has often been
weakened by methodological flaws. Therefore, it is diffi-
cult to compare home telemonitoring with usual care
for the chronic diseases studied [25]. eNephro is the first
medicoeconomic study designed to evaluate the benefits
of home telemonitoring for CKD patients at different
stages. The implementation of telemedicine applications
differs from other health interventions, such as the use
of medications or devices, in that these applications con-
tain several interacting components and have effects that
are highly dependent on the local context in which they
take place. Evaluating such interventions, qualified as
complex interventions [26], raises practical and meth-
odological issues that researchers have to take into ac-
count. Guidance for developing and evaluating complex
interventions was published by the Medical Research
Council in 2008 [26]. Later, national and international
templates for the specific evaluation of telemedicine pro-
jects, integrating general recommendations about the as-
sessment of complex interventions, were published in
2012-13 (HAS [27], MAST [28]). All templates emphasize
the need for a comparative design [29], but acknowledge
the trade-off between methodological requirements to en-
sure internal validity and the necessity to permit a degree
of flexibility or tailoring of the assessed intervention. En-
suring strict fidelity to a protocol (e.g. medications trials)
may be inappropriate as the intervention may work better
if adaptation to the local setting is allowed. The choice of
a pragmatic trial for our evaluation combines the
methodological requirements (comparative design andrandomisation) and the necessary flexibility in the im-
plementation of the intervention. Templates also
underscore the usefulness of multiple outcomes and the
integration of patients’ and professionals’ points of view,
important aspects included in the eNephro evaluation.
Moreover, the effects of telemedicine on patient health –
clinical parameters, morbidity, mortality, health-related
quality-of-life – are evaluated and all resources used are
considered in the cost evaluation, according to the above-
mentioned recommendations. The French health insur-
ance database (SNIIRAM) appears to offer the best way to
estimate medical expenditures incurred for a given patient
during a given period. SNIIRAM records data for all
healthcare beneficiaries in France, and includes the reim-
bursed costs of all out-of-hospital healthcare consump-
tions, as well as all hospital stays and consultations in
public or private institutions [30]. Finally, the acceptability
of the telemedicine system and satisfaction with its use are
assessed, as recommended, for all stakeholders, i.e. pa-
tients randomised to intervention groups and health pro-
fessionals involved in the home telemonitoring.
Many types of results are expected to come forward.
For patients with stage 3B/4 CKD, eNephro home telemo-
nitoring should allow enhanced follow-up since clinical and
biological information will be recorded regularly by the data
platform. It is also expected that the expert systems identi-
fies early situations where patients risk for decompensation
and/or deterioration of their health status, even before the
development of clinical symptoms prompt them to seek
medical assistance. This should enable more rapid medical
intervention and a lower rate of hospitalisation. Better con-
trol of blood pressure and proteinuria should delay the
need for more aggressive care with replacement therapy.
For patients on home and out centre dialysis (haemodialysis
or peritoneal dialysis), regular transmission of data issuing
from various sources (patient, health practitioners, medical
devices, medical laboratories) should lead to earlier and
more rapid care for complications, with a reduction in the
need for hospitalisation, an important source of medical ex-
penditure in this population. It has been demonstrated that
an expert system evaluating the state of hydration of pa-
tients on peritoneal dialysis enables a considerable reduc-
tion in the number of hospitalisations for acute pulmonary
oedema [19]. Furthermore, knowing one is under telesur-
veillance and that important health data can be transmitted
quickly is reassuring. For patients on haemodialysis, the
transmission of data issuing from the generator during the
dialysis session improves the detection of problems involv-
ing a malaise [31] or the vascular access [18]. Transplant re-
cipients should also benefit from telesurveillance facilitated
by a specifically designed expert system [12], and the num-
ber of visits to the transplantation centre may be limited
when clinical and biological parameters remain within tar-
get ranges.
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routine practices, implying to adapt and reorganise the
physicians work schedule. It’s necessary to fix daily time
slots for monitoring alerts, communicating with patients,
or adapting treatments. As the mass of data generated
by the system is significant, a telemedicine coordinator
(e.g. a coordinating nurse) seems to be necessary to deal
with all information transmitted. The reduction in the
need for in-centre visits undoubtedly releases time for
this new allotment. The acceptability of a telemedicine
system by physicians depends heavily upon the capacity
for optimal reorganisation, and the realisation that home
telemonitoring activity is not simply an added work load.
The clinical situations requiring management should
be less complicated, and thus less time demanding
since detected earlier by the expert system. Home tel-
emonitoring also facilitates communication and co-
operation between specialists, disciplines, and referral
levels (nephrology – 2nd line referral, general medicine –
1st line referral), undoubtedly leading to improved
patient-centred care. All of these elements join together to
facilitate the delivery of higher quality care, a common
goal for patients, professionals and healthcare systems.
For the healthcare system, home telemonitoring also
contributes to cost containment by limiting the need for
patient transportation, by reducing the number of in-
centre visits, hospitalisations and by favouring early care
for deteriorated health status and by preventing compli-
cations. In the eNephro study, it is expected that the
costs generated by the telemedicine system are counter-
balanced by lower overall healthcare costs. In this case,
the results would be an important argument favouring
reimbursement of home telemonitoring costs by the na-
tional health insurance fund.
This study can be expected to identify barriers and fa-
cilitators for implementing a home telemonitoring sys-
tem as well as profiles of patients most likely to benefit
from this new care system.
The first patient was enrolled in the eNephro study on
November 27, 2015. At the time this article was submit-
ted, a total of 259 patients (127 telemedicine patients;
132 control patients) had been enrolled.
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